Stocks
ANI Pharmaceuticals Financial Statements (ANIP) |
||||||||||
| ANI Pharmaceuticalssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 27.02.2020 | 11.03.2021 | 15.03.2022 | 09.03.2023 | 29.02.2024 | 08.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 206.5 | 208.5 | 216.1 | 316.4 | 486.8 | 555.5 | |||
| Operating Income, bln rub | 16.4 | -16.1 | -32.5 | -25.1 | 47.0 | 8.78 | ||||
| EBITDA, bln rub | ? | 60.7 | 29.1 | -1.68 | 48.1 | 109.3 | 64.0 | |||
| Net profit, bln rub | ? | 6.09 | -22.5 | -42.6 | -47.9 | 18.8 | -7.09 | |||
| OCF, bln rub | ? | 45.6 | 15.3 | 3.32 | -31.2 | 119.0 | 92.9 | |||
| CAPEX, bln rub | ? | 27.5 | 68.3 | 23.6 | 16.5 | 18.5 | 22.8 | |||
| FCF, bln rub | ? | 18.1 | -53.1 | -20.3 | -47.7 | 100.4 | 88.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.190 | 1.63 | 1.63 | 1.63 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 8.65% | -22.9% | ||||
| OPEX, bln rub | 127.0 | 136.9 | 143.7 | 203.3 | 196.0 | 341.8 | ||||
| Cost of production, bln rub | 63.2 | 87.2 | 100.6 | 138.8 | 181.5 | 267.9 | ||||
| R&D, bln rub | 19.8 | 16.0 | 11.4 | 22.3 | 34.3 | 37.8 | ||||
| Interest expenses, bln rub | 13.0 | 9.45 | 11.9 | 28.1 | 26.9 | 17.2 | ||||
| Assets, bln rub | 456.8 | 461.2 | 771.6 | 760.1 | 904.4 | 1 287 | ||||
| Net Assets, bln rub | ? | 212.8 | 195.7 | 358.7 | 338.5 | 432.7 | 430.8 | |||
| Debt, bln rub | 185.7 | 185.7 | 287.4 | 286.5 | 285.7 | 625.4 | ||||
| Cash, bln rub | 62.3 | 7.86 | 100.3 | 48.2 | 221.1 | 145.0 | ||||
| Net debt, bln rub | 123.4 | 177.8 | 187.1 | 238.3 | 64.5 | 480.4 | ||||
| Ordinary share price, rub | 61.7 | 29.0 | 46.1 | 40.2 | 55.1 | 62.6 | ||||
| Number of ordinary shares, mln | 11.8 | 12.0 | 12.6 | 16.3 | 18.0 | 19.4 | ||||
| Market cap, bln rub | 730 | 347 | 580 | 654 | 993 | 1 214 | ||||
| EV, bln rub | ? | 854 | 525 | 767 | 892 | 1 057 | 1 694 | |||
| Book value, bln rub | 29 | 4 | 37 | 59 | 196 | -199 | ||||
| EPS, rub | ? | 0.51 | -1.88 | -3.38 | -2.95 | 1.04 | -0.37 | |||
| FCF/share, rub | 1.53 | -4.43 | -1.61 | -2.93 | 5.58 | 4.54 | ||||
| BV/share, rub | 2.43 | 0.30 | 2.92 | 3.61 | 10.9 | -10.3 | ||||
| EBITDA margin, % | ? | 29.4% | 13.9% | -0.78% | 15.2% | 22.5% | 11.5% | |||
| Net margin, % | ? | 2.95% | -10.8% | -19.7% | -15.1% | 3.86% | -1.28% | |||
| FCF yield, % | ? | 2.48% | -15.3% | -3.50% | -7.29% | 10.1% | 7.26% | |||
| ROE, % | ? | 2.86% | -11.5% | -11.9% | -14.1% | 4.34% | -1.65% | |||
| ROA, % | ? | 1.33% | -4.89% | -5.52% | -6.30% | 2.08% | -0.55% | |||
| P/E | ? | 119.8 | -15.4 | -13.6 | -13.7 | 52.9 | -171.2 | |||
| P/FCF | 40.4 | -6.55 | -28.6 | -13.7 | 9.88 | 13.8 | ||||
| P/S | ? | 3.54 | 1.67 | 2.69 | 2.07 | 2.04 | 2.19 | |||
| P/BV | ? | 25.3 | 96.3 | 15.8 | 11.1 | 5.08 | -6.09 | |||
| EV/EBITDA | ? | 14.1 | 18.1 | -455.8 | 18.6 | 9.67 | 26.5 | |||
| Debt/EBITDA | 2.03 | 6.12 | -111.1 | 4.96 | 0.59 | 7.51 | ||||
| R&D/CAPEX, % | 71.9% | 23.4% | 48.1% | 135.6% | 185.2% | 165.5% | ||||
| CAPEX/Revenue, % | 13.3% | 32.8% | 10.9% | 5.20% | 3.80% | 4.11% | ||||
| ANI Pharmaceuticals shareholders | ||||||||||
